Banking on hope, swayed by hype? Hydroxychloroquine in the time of Covid-19
As coronavirus deaths amassed and already stretched health care systems in Europe, and the United States groaned with the added weight of the pandemic, the FDA and EMA agencies adopted contradictory tones over the use of a pair of decades-old malaria drugs to fight the virus — epitomizing the desperation to combat an uncharted disease.
“This is just another example that points to the fact that while EMA and FDA oftentimes take the same position, they also take contrary positions,” said Peter Pitts, who served as the FDA’s associate commissioner for external relations between 2002 and 2004. “We are addressing Covid-19 in a variety of ways, and so is the EMA — the circles are concentric, but they are not identical.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.